FindTrial
Sign In

The outcome of chemoradiotherapy for NSCLC - EGFR mutant vs wild-type -

The impact of EGFR mutations on outcomes after chemoradiotherapy for locally advanced non small cell lung cancer: a systematic review and meta-analysis - The impact of EGFR mutations on outcomes after CRT for LA-NSCLC: a systematic review and meta-analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000055584
Enrollment
Unknown
Registered
2024-09-24
Start date
2024-10-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non small cell lung cancer

Interventions

None listed

Sponsors

JAPANESE RED CROSS ISE HOSPITAL, Department of Radiation Oncology, Satoru Ochiai
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria were: (i) studies reporting survival outcomes following CRT for LA-NSCLC; (ii) studies comparing survival outcomes between EGFR mutant

Exclusion criteria

Exclusion criteria: Exclusion criteria were: (i) non-English publications; (ii) studies including patients receiving targeted therapy or immunotherapy; (iii) studies involving radiotherapy alone.

Design outcomes

Primary

MeasureTime frame
progression-free survival and overall survival—

Secondary

MeasureTime frame
post-progression survival, patterns of disease progression—

Countries

Japan

Contacts

Public ContactSatoru Ochiai

JAPANESE RED CROSS ISE HOSPITAL Department of Radiation Oncology

sochiamn@gmail.com0596-28-2171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026